BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 40,000 shares of the firm's stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $73.97, for a total transaction of $2,958,800.00. Following the transaction, the chief executive officer directly owned 735,686 shares in the company, valued at $54,418,693.42. This represents a 5.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Neil Kumar also recently made the following trade(s):
- On Monday, December 15th, Neil Kumar sold 30,011 shares of BridgeBio Pharma stock. The stock was sold at an average price of $74.64, for a total value of $2,240,021.04.
- On Thursday, December 4th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $74.40, for a total value of $2,976,000.00.
- On Thursday, November 20th, Neil Kumar sold 26,156 shares of BridgeBio Pharma stock. The shares were sold at an average price of $65.84, for a total value of $1,722,111.04.
- On Thursday, November 6th, Neil Kumar sold 40,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $63.15, for a total value of $2,526,000.00.
BridgeBio Pharma Stock Down 0.5%
BBIO stock opened at $76.84 on Tuesday. The company has a market cap of $14.81 billion, a PE ratio of -18.38 and a beta of 1.17. BridgeBio Pharma, Inc. has a 52 week low of $28.10 and a 52 week high of $78.58. The business has a 50-day simple moving average of $71.75 and a 200 day simple moving average of $58.17.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its earnings results on Wednesday, October 29th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). The firm had revenue of $120.70 million for the quarter, compared to the consensus estimate of $107.71 million. During the same period in the previous year, the firm earned ($0.86) EPS. The company's quarterly revenue was up 4318.0% on a year-over-year basis. On average, analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.
Hedge Funds Weigh In On BridgeBio Pharma
Several large investors have recently modified their holdings of the business. Norges Bank bought a new stake in shares of BridgeBio Pharma in the second quarter worth $84,488,000. Invesco Ltd. increased its stake in shares of BridgeBio Pharma by 40.3% in the third quarter. Invesco Ltd. now owns 3,928,657 shares of the company's stock valued at $204,054,000 after buying an additional 1,127,592 shares during the period. Polar Capital Holdings Plc bought a new position in shares of BridgeBio Pharma during the third quarter worth about $50,956,000. Wellington Management Group LLP lifted its stake in shares of BridgeBio Pharma by 1,698.5% in the third quarter. Wellington Management Group LLP now owns 1,019,194 shares of the company's stock worth $52,937,000 after acquiring an additional 962,525 shares during the period. Finally, Franklin Resources Inc. increased its position in BridgeBio Pharma by 75.8% during the 3rd quarter. Franklin Resources Inc. now owns 1,444,023 shares of the company's stock valued at $75,003,000 after purchasing an additional 622,618 shares during the period. Institutional investors own 99.85% of the company's stock.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on the company. JPMorgan Chase & Co. lifted their target price on BridgeBio Pharma from $76.00 to $77.00 and gave the company an "overweight" rating in a research report on Friday, November 7th. Piper Sandler lifted their price target on shares of BridgeBio Pharma from $93.00 to $98.00 and gave the company an "overweight" rating in a report on Thursday, October 30th. Cantor Fitzgerald increased their price objective on shares of BridgeBio Pharma from $100.00 to $110.00 and gave the company an "overweight" rating in a research note on Thursday, October 30th. Wells Fargo & Company boosted their target price on shares of BridgeBio Pharma from $76.00 to $84.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 11th. Finally, Evercore ISI reiterated an "outperform" rating on shares of BridgeBio Pharma in a report on Monday, October 27th. Twenty-two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, BridgeBio Pharma presently has an average rating of "Moderate Buy" and an average price target of $78.85.
Check Out Our Latest Report on BridgeBio Pharma
BridgeBio Pharma Company Profile
(
Get Free Report)
BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.
BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
